BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment. Its first asset, Plinabulin is a novel brain-penetrant microtubule modulator with dendritic cell maturation and vasculature modulation mechanism, which has the potential to help mitigate acquired resistance from prior immune checkpoint inhibitors (ICI) treatment in cancer patients. It is a Selective Immunomodulating Microtubule-Binding Agent (SIMBA), which may provide multiple therapeutic opportunities.
Last trade$0.00
Day change$0.00 (0.00%)
Day range$0.563 – $0.63
Volume10,614
Market cap$24M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$24.02M
Price / earnings
—
Price / book
-0.68×
Price / sales
—
EV / sales
—
EV / EBITDA
-2.54×
Profitability
Earnings per share
-$0.16
Return on assets
-45.77%
Return on equity
18.8%
Dividend yield
0%
Liquidity and leverage
Debt / equity
-0×
Current ratio
1.66×
Quick ratio
1.66×
Cash ratio
0.45×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$16.75M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for BYSI, quarterly periods
Line item
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Q3 FY2024 Sep 30, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$758K
$1.16M
$1.12M
$751K
$947K
$1.74M
$1.23M
$1.74M
Research and development
$973K
$1.08M
$1.47M
$1.04M
$1M
$874K
$472K
$622K
Total operating expenses
$1.73M
$2.23M
$2.6M
$1.79M
$1.95M
$2.61M
$1.7M
$2.36M
Operating income
-$1.73M
-$2.23M
-$2.6M
-$1.79M
-$1.95M
-$2.61M
-$1.7M
-$2.36M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$1.65M
-$2.16M
-$2.49M
-$1.72M
-$1.86M
-$2.56M
-$1.82M
-$2.22M
Income taxes
$100K
$192K
$22K
$26K
$22K
$20K
$96K
$0
Net income
-$5.7M
-$6.67M
-$15.24M
-$1.5M
-$4.65M
$1.17M
-$7.1M
-$2.22M
Net income attributable to common shareholders
-$849K
-$2.16M
-$2.14M
-$1.54M
-$1.81M
$4.48M
-$1.73M
-$2.13M
EBITDA
-$1.71M
-$2.21M
-$2.75M
-$1.71M
-$1.87M
-$2.53M
-$1.68M
-$2.28M
Basic earnings per share
-$0.02
-$0.05
-$0.05
-$0.04
-$0.04
$0.11
-$0.04
-$0.05
Diluted earnings per share
-$0.02
-$0.05
-$0.05
-$0.04
-$0.04
$0.11
-$0.04
-$0.05
Recent news
Company coverage with links to the original publishers.
SEED Therapeutics received FDA designations for its lead oncology asset ST-01156, a molecular glue that degrades RBM39. The company also announced strategic transactions with its largest shareholder, BeyondSpring, to diversify its shareholder base.
BeyondSpring announced the sale of a portion of its equity interest in SEED Therapeutics for $35.4 million. The proceeds will be used to advance the late-stage clinical trials of BeyondSpring's lead asset, Plinabulin, a first-in-class anti-cancer agent.
BeyondSpring presented updated results from a phase 2 study evaluating a triple combination of pembrolizumab, plinabulin, and docetaxel in metastatic NSCLC patients who progressed on prior immune checkpoint inhibitors. The regimen showed promising efficacy with a disease control rate of 89.3% and median PFS of 8.6 months.
BeyondSpring's plinabulin/docetaxel combination demonstrated significant improvements in overall survival, progression-free survival, and objective response rate compared to docetaxel alone, with an 80% reduction in grade 4 neutropenia and improved patient quality of life.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.